peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

cyclic depsipeptide

Plitidepsin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

Plitidepsin was found to inhibit host-cell protein synthesis (cellular translation).

Sources[4]pubmedCan plitidepsin be used as an antiviral against RSV?Overall, our results show that plitidepsin blocks cellular translation
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Overall, our results show that plitidepsin blocks cellular translation”

    Can plitidepsin be used as an antiviral against RSV? · UNLABELLED

    pubmed:41277830:d863e9c9565c:d863e9c9565c

Mechanism

Plitidepsin is described as targeting eEF1A, a host translation elongation factor responsible for delivering aminoacyl-tRNA (tRNA-aa) to the ribosome.

Sources[4]pubmedCan plitidepsin be used as an antiviral against RSV?the target of plitidepsin has been identified as the cellular protein eukaryotic translation elongation factor 1A (eEF1A) that brings tRNA-aa to the ribosome
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “the target of plitidepsin has been identified as the cellular protein eukaryotic translation elongation factor 1A (eEF1A) that brings tRNA-aa to the ribosome”

    Can plitidepsin be used as an antiviral against RSV? · IMPORTANCE

    pubmed:41277830:d863e9c9565c:d863e9c9565c

What has been studied?

What the evidence says.

Comparative evidence

The ADMYRE study is described as a randomized phase III trial in relapsed/refractory multiple myeloma comparing plitidepsin + low-dose dexamethasone against low-dose dexamethasone alone.

Sources[5]pubmedPlitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.P plus low-dose dexamethasone (LD-DXM) was evaluated versus LD-DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM) in the randomized phase III ADMYRE trial.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “P plus low-dose dexamethasone (LD-DXM) was evaluated versus LD-DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM) in the randomized phase III ADMYRE trial.”

    Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. · Abstract

    pubmed:41545603:a56ed06f5873:a56ed06f5873

Comparative evidence

ADMYRE was a phase III comparative study assessing plitidepsin combined with dexamethasone against dexamethasone monotherapy in relapsed/refractory multiple myeloma.

Sources[3]pubmedRandomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years.Background:The phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Background:The phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM).”

    Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years. · Abstract

    pubmed:41228275:647b5c007b1f:647b5c007b1f

Comparative evidence

Because a randomized head-to-head study was absent, an external control arm approach using individual patient-level data from multiple pomalidomide + low-dose dexamethasone trials was used to match and compare against ADMYRE plitidepsin + low-dose dexamethasone data.

Sources[5]pubmedPlitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.In absence of a randomized study with P + LD-DXM vs. POM + LD-DXM, a direct matched comparison between P + LD-DXM (ADMYRE data) and pomalidomide (POM) + LD-DXM as an External Control Arm (ECA) was conducted using individual patient-level data from several contemporary POM + LD-DXM trials with a similar design.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In absence of a randomized study with P + LD-DXM vs. POM + LD-DXM, a direct matched comparison between P + LD-DXM (ADMYRE data) and pomalidomide (POM) + LD-DXM as an External Control Arm (ECA) was conducted using individual patient-level data from several contemporary POM + LD-DXM trials with a similar design.”

    Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. · Abstract

    pubmed:41545603:a56ed06f5873:a56ed06f5873

Study findings

In a 3-day cell-based growth inhibition assay, CHEMBL451930 inhibited proliferation of human HT-29 cells with an IC50 of 0.5 nM.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL451930Assay: Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.5 nM
Reported result
IC50 = 0.5 nM
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Assay: Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.5 nM”

    ChEMBL activities for CHEMBL451930 · Activity 24998060

    chembl-activities:chembl451930:1f8155fd441f:1f8155fd441f

Study findings

In a cell-based proliferation assay, CHEMBL451930 produced potent growth inhibition of mouse P388 cells, with an IC50 of 0.2 nM measured after 3 days of incubation.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL451930Assay: Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.2 nM
Reported result
IC50 = 0.2 nM
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Assay: Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.2 nM”

    ChEMBL activities for CHEMBL451930 · Activity 24998054

    chembl-activities:chembl451930:1f8155fd441f:1f8155fd441f

Study findings

In a 3-day cell-based growth inhibition assay, CHEMBL451930 inhibited proliferation of human A549 cells with an IC50 of 0.2 nM.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL451930Assay: Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.2 nM
Reported result
IC50 = 0.2 nM
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Assay: Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 3 days Assay format: cell-based format Standard result: IC50 = 0.2 nM”

    ChEMBL activities for CHEMBL451930 · Activity 24998057

    chembl-activities:chembl451930:1f8155fd441f:1f8155fd441f

Study findings

The source states plitidepsin’s initial development program was for oncology (anti-tumor use).

Sources[2]pubmedPharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor.was originally developed as an anti-tumor drug,
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “was originally developed as an anti-tumor drug,”

    Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. · Abstract

    pubmed:41218566:50493b443471:50493b443471

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, regulatory, safety
  • 84 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (48), assurance_score_below_0.72 (33), current_regulatory_source_required (16), extraction_ambiguity (75), high_risk_requires_regulatory_or_two_independent_sources (35), no_direct_support (81)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. ChEMBL activities for CHEMBL451930 ↗

    chembl-activities · published 2026-08-29 · retrieved 2026-08-29T08:37:13Z

  2. Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor. ↗

    pubmed · published 2025-12-01 · retrieved 2026-08-29T08:37:13Z

  3. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years. ↗

    pubmed · published 2025-10-29 · retrieved 2026-08-29T08:37:13Z

  4. Can plitidepsin be used as an antiviral against RSV? ↗

    pubmed · published 2025-12-23 · retrieved 2026-08-29T08:37:13Z

  5. Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. ↗

    pubmed · published 2026-01-17 · retrieved 2026-08-29T08:37:13Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-29T08:37:13Z

19dce4d7e3c80f7cebd8d8a6c9af0fe9079b0f5efe578f0ea2dec4b0a5374b35